AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17568029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 16179042 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at extra 1 point
Number of subjects: 76
Study 16179042 — intervention group
Group type: COMPARATOR
Intervention: Acupressure at an inappropriate site (Control)
Number of subjects: 76
Study 12113651 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pimecrolimus 1.0% cream applied twice daily for 3 weeks in adults
Number of subjects: 0
Study 12113651 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pimecrolimus 1.0% cream applied twice daily for 6 weeks in infants and children
Number of subjects: 0
Study 12113651 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pimecrolimus 1.0% cream
Number of subjects: 0
Study 12113651 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pimecrolimus 1.0% cream (intermittent long-term use)
Number of subjects: 0
Study 12113651 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pimecrolimus 1.0% cream for 1 year
Number of subjects: 0
Study 10569156 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical intrastromal steroid (prednisolone sodium phosphate 1% solution) applied on the undersurface of the cap immediately after it was reflected.
Number of subjects: 210
Study 10569156 — intervention group
Group type: COMPARATOR
Intervention: Standard LASIK medication protocol (no steroid application).
Number of subjects: 210
Study 7546467 — intervention group
Group type: EXPERIMENTAL
Intervention: VariGlass VLC glass ionomer
Number of subjects: 48
Study 7546467 — intervention group
Group type: EXPERIMENTAL
Intervention: Concise resin sealants
Number of subjects: 48
Study 2125793 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 1.0 mg
Number of subjects: 10
Study 2125793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 377458 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute excision (A) - operation within 24 hours post burn
Number of subjects: 2460
Study 377458 — intervention group
Group type: COMPARATOR
Intervention: Exposure method (E) - exposure followed by excision and transplantation no later than day 14 post burn
Number of subjects: 2460
Study 31975316 — intervention group
Group type: EXPERIMENTAL
Intervention: Red clover preparation (Promensil® Forte) 80 mg/day for 24 months
Number of subjects: 81
Study 31975316 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one oral tablet/day without active ingredient)
Number of subjects: 81
Study 31473079 — intervention group
Group type: EXPERIMENTAL
Intervention: KnowIt
Number of subjects: 0
Study 31473079 — intervention group
Group type: EXPERIMENTAL
Intervention: OnTrack
Number of subjects: 0
Study 28724914 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer‐based cognitive training on six adaptive tests of executive function
Number of subjects: 318
Study 28724914 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive and physical exercise training
Number of subjects: 318
Study 28724914 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training combined with non‐invasive brain stimulation and physical exercise training
Number of subjects: 318
Study 28724914 — intervention group
Group type: COMPARATOR
Intervention: Active control training in adaptive visual search and change detection tasks
Number of subjects: 318
Study 28724914 — intervention group
Group type: COMPARATOR
Intervention: Passive control
Number of subjects: 318
Study 25837216 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger 1000mg/d for 10 weeks
Number of subjects: 36
Study 25837216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 24028998 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased T-wave alternans (TWA) and QT variability (QTV) combined (specifically IAA90 and QTVN)
Number of subjects: 175
Study 24028998 — intervention group
Group type: EXPERIMENTAL
Intervention: TWA
Number of subjects: 175
Study 24028998 — intervention group
Group type: EXPERIMENTAL
Intervention: QTV
Number of subjects: 175
Study 22071707 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncalibrated energy consumption (20% increment)
Number of subjects: 74155
Study 22071707 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-calibrated energy consumption (20% increment)
Number of subjects: 74155
Study 22071707 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncalibrated energy consumption (20% increment) after adjustment for BMI
Number of subjects: 74155
Study 22071707 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncalibrated protein intake (g/d) (20% increment)
Number of subjects: 74155
Study 22071707 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-calibrated protein intake (g/d) (20% increment)
Number of subjects: 74155
Study 22071707 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncalibrated protein intake (g/d) (20% increment) after adjustment for BMI
Number of subjects: 74155
Study 22071707 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncalibrated protein density (% of energy from protein) (20% increment)
Number of subjects: 74155
Study 22071707 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-calibrated protein density (% of energy from protein) (20% increment)
Number of subjects: 74155
Study 22071707 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncalibrated protein density (% of energy from protein) (20% increment) after adjustment for BMI
Number of subjects: 74155
Study 19750191 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) program
Number of subjects: 284
Study 19750191 — intervention group
Group type: COMPARATOR
Intervention: Control group (treated only with drugs)
Number of subjects: 284
Study 19750191 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study group
Number of subjects: 284
Study 19750191 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLD stages 2, 3, and 4
Number of subjects: 284
Study 19750191 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLD stage 1
Number of subjects: 284
Study 16894423 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPA(+) method
Number of subjects: 82
Study 16894423 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc-DTPA plasma disappearance curve
Number of subjects: 82
Study 16894423 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPA(-) method
Number of subjects: 82
Study 16894423 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma clearance of creatinine by 24-hour urine collection
Number of subjects: 82
Study 16894423 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma clearance of creatinine by Cockcroft-Gault formula
Number of subjects: 82
Study 16894423 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionuclidic methods (DTPA(+), DTPA(-), (99m)Tc-DTPA)
Number of subjects: 82
Study 16894423 — intervention group
Group type: COMPARATOR
Intervention: Creatinine clearance with 24-hour urine collection
Number of subjects: 82
Study 12520563 — intervention group
Group type: EXPERIMENTAL
Intervention: Rank-based procedures for testing non-inferiority and equivalence hypotheses
Number of subjects: 0
Study 12520563 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-parametric procedures
Number of subjects: 0
Study 11093989 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg (D10)
Number of subjects: 225
Study 11093989 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 5 mg (D5)
Number of subjects: 225
Study 11093989 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 2.5 mg (D2.5)
Number of subjects: 225
Study 11093989 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 1.25 mg (D1.25)
Number of subjects: 225
Study 11093989 — intervention group
Group type: COMPARATOR
Intervention: Saline (S)
Number of subjects: 225
Study 8936243 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion needs identification
Number of subjects: 148
Study 1357295 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous adrenaline (0.1 microgram/kg)
Number of subjects: 12
Study 1357295 — intervention group
Group type: COMPARATOR
Intervention: Tracheal adrenaline (0.5 microgram/kg)
Number of subjects: 12
Study 3908500 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of ciramadol
Number of subjects: 343
Study 3908500 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of ciramadol
Number of subjects: 343
Study 3908500 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of codeine
Number of subjects: 343
Study 3908500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study 31038010 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly-objectified women in alcohol advertisements
Number of subjects: 1208
Study 31038010 — intervention group
Group type: COMPARATOR
Intervention: Low-objectified women in alcohol advertisements
Number of subjects: 1208
Study 29314160 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 158
Study 29314160 — intervention group
Group type: COMPARATOR
Intervention: Systemic family therapy (SyFT)
Number of subjects: 158
Study 26996093 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient exercise-based rehabilitation program (n=32)
Number of subjects: 49
Study 26996093 — intervention group
Group type: COMPARATOR
Intervention: Respiratory physiotherapy regimen (n=17)
Number of subjects: 49
Study 23979965 — intervention group
Group type: EXPERIMENTAL
Intervention: Besifovir 90 mg daily
Number of subjects: 114
Study 23979965 — intervention group
Group type: EXPERIMENTAL
Intervention: Besifovir 150 mg daily
Number of subjects: 114
Study 23979965 — intervention group
Group type: COMPARATOR
Intervention: Entecavir 0.5 mg daily
Number of subjects: 114
Study 22845485 — intervention group
Group type: EXPERIMENTAL
Intervention: T'ai chi intervention (n=16)
Number of subjects: 28
Study 22845485 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group (n=12)
Number of subjects: 28
Study 20385794 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (80 microg/kg)
Number of subjects: 97
Study 20385794 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 97
Study 20385794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 18682881 — intervention group
Group type: EXPERIMENTAL
Intervention: (60)Cu-ATSM-PET imaging
Number of subjects: 17
Study 15699752 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Number of subjects: 0
Study 15699752 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 12654753 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg once daily for 3 days
Number of subjects: 48
Study 12654753 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1000 mg once daily for 3 days
Number of subjects: 48
Study 10668522 — intervention group
Group type: EXPERIMENTAL
Intervention: leflunomide
Number of subjects: 580
Study 10668522 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfasalazine
Number of subjects: 580
Study 10668522 — intervention group
Group type: EXPERIMENTAL
Intervention: methotrexate
Number of subjects: 580
Study 10668522 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 580
Study 8905480 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin 5 mg
Number of subjects: 8
Study 8905480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1715125 — intervention group
Group type: EXPERIMENTAL
Intervention: Imazodan 2 mg administered twice daily
Number of subjects: 147
Study 1715125 — intervention group
Group type: EXPERIMENTAL
Intervention: Imazodan 5 mg administered twice daily
Number of subjects: 147
Study 1715125 — intervention group
Group type: EXPERIMENTAL
Intervention: Imazodan 10 mg administered twice daily
Number of subjects: 147
Study 1715125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 1715125 — intervention group
Group type: EXPERIMENTAL
Intervention: Imazodan
Number of subjects: 147
Study 6869493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive skill remediation program (30 minutes per day, 3 days per week, for 3 weeks)
Number of subjects: 33
Study 6869493 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional therapies continued)
Number of subjects: 33
Study 30417848 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Bulk‐Fill Restorative (FBF)
Number of subjects: 80
Study 30417848 — intervention group
Group type: COMPARATOR
Intervention: Filtek Z250 (conventional composite)
Number of subjects: 80
Study 26821623 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg intravenous CsA
Number of subjects: 410
Study 26821623 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 410
Study 24556041 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX (oxaliplatin 85 mg/m², leucovorin 200 mg/m², bolus fluorouracil 400 mg/m², infusional fluorouracil 1600 mg/m²)
Number of subjects: 267
Study 24556041 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil and cisplatin (fluorouracil 1000 mg/m² per day for 4 days and cisplatin 75 mg/m² on day 1)
Number of subjects: 267
Study 24556041 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX
Number of subjects: 267
Study 24556041 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil and cisplatin
Number of subjects: 267
Study 22445676 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronome guidance
Number of subjects: 0
Study 22445676 — intervention group
Group type: COMPARATOR
Intervention: No metronome guidance (Control)
Number of subjects: 0
Study 20385926 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment for high-risk prethreshold ROP
Number of subjects: 401
Study 20385926 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment for Type 1 eyes
Number of subjects: 401
Study 20385926 — intervention group
Group type: COMPARATOR
Intervention: Conventional management for Type 1 eyes
Number of subjects: 401
Study 20385926 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment for Type 2 eyes
Number of subjects: 401
Study 20385926 — intervention group
Group type: COMPARATOR
Intervention: Conventional management for Type 2 eyes
Number of subjects: 401
Study 20385926 — intervention group
Group type: COMPARATOR
Intervention: Conventional management for high-risk prethreshold ROP
Number of subjects: 401
Study 18602754 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral coordinative exercise (CE)
Number of subjects: 115
Study 18602754 — intervention group
Group type: COMPARATOR
Intervention: Normal sport lesson (NSL)
Number of subjects: 115
Study 16157829 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA levels 0 to 0.49 ng/mL
Number of subjects: 5855
Study 16157829 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA levels 0.50 to 0.99 ng/mL
Number of subjects: 5855
Study 16157829 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA levels 1.00 to 1.49 ng/mL
Number of subjects: 5855
Study 16157829 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA levels 1.50 to 1.99 ng/mL
Number of subjects: 5855
Study 16157829 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA levels 2.00 to 2.49 ng/mL
Number of subjects: 5855
Study 16157829 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA levels 2.50 to 2.99 ng/mL
Number of subjects: 5855
Study 16157829 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA levels 3.00 to 3.99 ng/mL
Number of subjects: 5855
Study 16157829 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA levels 4.00 to 6.99 ng/mL
Number of subjects: 5855
Study 16157829 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA levels 7.00 to 9.99 ng/mL
Number of subjects: 5855
Study 16157829 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA levels 10.00 ng/mL or higher
Number of subjects: 5855
Study 16157829 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial PSA level less than 1 ng/mL
Number of subjects: 5855
Study 12392345 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional condition (reach to press a light switch to turn on a red light)
Number of subjects: 12
Study 12392345 — intervention group
Group type: COMPARATOR
Intervention: Semi-functional condition (reach to press the light switch; no light)
Number of subjects: 12
Study 12392345 — intervention group
Group type: COMPARATOR
Intervention: Nonfunctional condition (reach to a marker)
Number of subjects: 12
Study 9934423 — intervention group
Group type: EXPERIMENTAL
Intervention: Braced group (rehabilitative braces for 2 weeks, functional braces for 10 weeks)
Number of subjects: 60
Study 9934423 — intervention group
Group type: COMPARATOR
Intervention: Nonbraced group (no braces)
Number of subjects: 60
Study 9934423 — intervention group
Group type: EXPERIMENTAL
Intervention: Braced group
Number of subjects: 60
Study 9934423 — intervention group
Group type: COMPARATOR
Intervention: Nonbraced group
Number of subjects: 60
Study 7752005 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse doses of dexamethasone, 0.5 mg/kg per day, divided twice daily for 3 days at 10-day intervals
Number of subjects: 78
Study 7752005 — intervention group
Group type: COMPARATOR
Intervention: Saline solution placebo
Number of subjects: 78
Study 2281237 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression with paired Bernouilli outcomes
Number of subjects: 0
Study 7446190 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral ECT
Number of subjects: 29
Study 7446190 — intervention group
Group type: COMPARATOR
Intervention: Bilateral ECT
Number of subjects: 29
Study 31127593 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1500 mg/day)
Number of subjects: 60
Study 31127593 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study 28356319 — intervention group
Group type: EXPERIMENTAL
Intervention: Mealtime faster aspart
Number of subjects: 1143
Study 28356319 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmeal faster aspart
Number of subjects: 1143
Study 28356319 — intervention group
Group type: COMPARATOR
Intervention: IAsp
Number of subjects: 1143
Study 28356319 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 1143
Study 25918728 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 32
Study 25918728 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 32
Study 25918728 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness
Number of subjects: 32
Study 25918728 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 32
Study 24011655 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated thoracic manipulation (high velocity, low amplitude)
Number of subjects: 42
Study 24011655 — intervention group
Group type: COMPARATOR
Intervention: Sham group (same procedure without high-velocity thrust)
Number of subjects: 42
Study 24011655 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated thoracic manipulation
Number of subjects: 42
Study 24011655 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 42
Study 21865563 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 1132
Study 21865563 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid + iron supplementation
Number of subjects: 1132
Study 21865563 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid + iron + zinc supplementation
Number of subjects: 1132
Study 21865563 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation
Number of subjects: 1132
Study 21865563 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 1132
Study 19107946 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy
Number of subjects: 0
Study 19107946 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionated radiotherapy (SFX)
Number of subjects: 0
Study 17683563 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sigmoid resection
Number of subjects: 0
Study 17683563 — intervention group
Group type: COMPARATOR
Intervention: Open sigmoid resection
Number of subjects: 0
Study 15523952 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided PRK using the WASCA workstation and the Asclepion Meditec flying spot MEL 70 excimer laser
Number of subjects: 60
Study 15523952 — intervention group
Group type: COMPARATOR
Intervention: Conventional PRK using the same laser
Number of subjects: 60
Study 11176156 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse Ratio Ventilation (IRV)
Number of subjects: 22
Study 11176156 — intervention group
Group type: COMPARATOR
Intervention: Normal Ratio Ventilation
Number of subjects: 22
Study 10944051 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical intervention with ventilation tubes
Number of subjects: 182
Study 10944051 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 182
Study 10944051 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical intervention
Number of subjects: 182
Study 9072052 — intervention group
Group type: EXPERIMENTAL
Intervention: HELISAL
Number of subjects: 61
Study 1578091 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins B1, B2, and B6 (10 mg each)
Number of subjects: 14
Study 1578091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3881692 — intervention group
Group type: EXPERIMENTAL
Intervention: mesulergine
Number of subjects: 20
Study 3881692 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 31125491 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmutinib 100-300 mg
Number of subjects: 56
Study 29161901 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolaevulinic acid (ALA) PDT
Number of subjects: 58
Study 29161901 — intervention group
Group type: COMPARATOR
Intervention: Photofrin PDT
Number of subjects: 58
Study 26915064 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise group (80 dB verbal recording)
Number of subjects: 70
Study 26915064 — intervention group
Group type: COMPARATOR
Intervention: Control group (silence)
Number of subjects: 70
Study 25189917 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary treatment with sodium selenite, proteolytic plant enzymes and Lc-lectin
Number of subjects: 93
Study 22519543 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous nadroparin calcium (200 I.U./kg/day) for 6 weeks
Number of subjects: 24